Category Archives: DNA

HASTINGS, Mich. (WOOD) Ashley Copelin was 2 months old when her mom left the family home in Barryton, a small village east of Big Rapids, for a gallon of milk. They were living with grandpa and grandma.

That was on May 17, 1987.

Nobody has seen her mom, Margie Ann Ranshaw, in the nearly 35 years since.

I just want people to know her name, Copelin said on Friday.

She said recent breakthroughs in missing persons cases in Kent and Ottawa counties are giving her renewed hope for her moms case which quickly went cold.

I dont believe that shes alive, she said. But I do believe that her body is out there somewhere, and I do believe that we deserve to know what happened to her, regardless if shes dead or not.

Her mom was 29 when she vanished. Shed be turning 64 this month.

In NAMUS, the National Missing and Unidentified Persons System, shes listed as Missing Person Case No. 14788.

She was sick. She had schizophrenia, Copelin said of her mom. She told my grandfather right before she left that the voices were telling her to leave, and my grandfather was telling her she had to fight through that and she had to ignore those voices.

Her mom, she said, had dreams of living out west.

She would often hitchhike and she would be gone for months at a time. She would always come back, Copelin said.

This time, police found her car abandoned two weeks later two hours away at a hotel in Howell. Most of her family believes she was the victim of foul play.

The investigation by the Mecosta County Sheriffs Department never turned up any answers.

An aunt and uncle adopted and raised the missing moms daughter.

I had a great life, and I had a great childhood, Copelin said.

She now is raising two kids of her own in Hastings.

There was a hole missing in my heart, and I had pain that stuck with me my whole entire life, she said.

She has tried finding her mom on her own background searches, Google searches with an outside hope that shes still alive.

No matter what kind of research I do, no matter what I do, it comes to a dead-end with her, she said. And I believe, I have come to the conclusion that its something that maybe God doesnt want to reveal.

She reached out to Target 8 after learning that genealogy researchers working with DNA had identified two bodies found decades ago in West Michigan: remains previously known as Ada Bones in Kent County and Matilda in Ottawa County.

It gives me a lot of hope, she said. Some families are getting their justice 40, 45 years later, and Im hoping for that chance ourselves.

Her mom is among 619 people listed by NAMUS as missing from Michigan. Anyone with information on this case is asked to call the Mecosta County Sheriffs Department at 231.592.0150.

See the rest here:
DNA breakthroughs give new hope to daughter of missing mom - WOODTV.com

Massimo Giachetti/iStock Editorial via Getty Images

Codex DNA (DNAY) is a $267m market cap biotech that IPOd in June last year, raising $123m at $16 per share. The company was spun out of Synthetic Genomics (since renamed Viridos) in 2019, having been founded under the name SGI-DNA in 2013 - co-founder Thomas Gibson developed the Gibson assembly method of cloning DNA, and currently serves as Chief Technology Officer.

The company described itself as follows in its IPO prospectus:

We believe that we are a leading synthetic biology company focused on enabling researchers to rapidly, accurately and reproducibly build or write high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology enabled markets.

A key part of our solution is our BioXp system, an end-to-end automated workstation that fits on the benchtop and is broadly accessible due to its ease-of-use and hands-free automation.

We believe our BioXp system can democratize synthetic biology by simplifying the process of building DNA and mRNA, thereby accelerating the discovery, development and production of novel high-value products, including antibody-based biologics, mRNA-based vaccines and therapeutics and precision medicines.

The list of companies that either have been or are currently using Codex' instruments and consumables includes reputed academic institutions such as Duke University, the Memorial Sloan Kettering Cancer Center, and MiT, large pharmas including Johnson & Johnson (JNJ), Eli Lilly (LLY) and Merck (MRK), gene therapy specialist Editas (EDIT) and even BioNTech, co-developer of the $36bn selling (in 2021) Comirnaty COVID vaccine, alongside Pfizer (PFE).

Codex says it has ~160 installed bases of BioXp, and reported earnings of $2.2m in Q321 - up 69% year-on-year, and up from $2.12m in Q221. Year-to-date earnings in Q321 were reported as $8m - up from $6.6m across the whole of 2020, and $4.8m in 2019 (according to a recent investor presentation).

These are not sales figures to make investors tingle with anticipation, and so it has proven - Codex' share price since its IPO has been on a downtrend, falling from a high of $22 in June last year, to a low of $6.2 by late December.

Things may be about to change for Codex and its valuation, however, thanks to a partnership agreed with Pfizer, who will make an initial upfront payment of $8m for the right to firstly collaborate on improving, and then to use Codex' platforms and instruments to "produce certain materials of interest to Pfizer."

According to an 8k filing by Codex, there's a further $10m on the table in the near term if Codex meets "certain technical milestones," and if Pfizer successfully develops products using the technology, up to $60m in clinical development milestone payments, and $180m in sales milestones per exclusive product.

When announced in late December, the news of the deal sparked a brief rally in Codex stock, to $11 per share, which has since fallen to $9.25 per share. It may not seem like much, but the long-term implications of the deal could be hugely significant.

Pfizer shares rose in value by ~50% last year, and of all the major pharmaceuticals, looks to have the most momentum going into the new year. This is primarily down to its co-development of Comirnaty alongside BioNTech, the Germany based biotech that is considered, alongside Moderna (MRNA) to be the world's premier developer of messenger-RNA technologies.

Even so, without BioNTech at its side, Pfizer showed it can develop specialist drugs of its own in 2021 with the development of Paxlovid - an oral antiviral that reduced the risk of COVID-19-associated hospitalization or death by 89% in those who received treatment within three days of symptom onset.

Pfizer's CEO Albert Bourla has occasionally made noise about pursuing mRNA technologies without BioNTech as a partner, and as small as the Codex deal is for a pharma of Pfizer's size - its current market cap stands at $312bn - it seems to be a clear indication that the company has ambitions in this space.

We may not see much in the way of value adding developments on Pfizer's part in 2022 - neither Moderna nor BioNTech have made much tangible progress with mRNA outside of the COVID vaccine space yet, although both have assets targeting types of solid tumor cancer, as well as vaccines focused on viruses including Respiratory Syncytial Virus ("RSV"), influenza, and others - but Pfizer's decision to partner with Codex could have a very positive influence on the biotech's reputation and share price this year.

Codex' platform spans both synthetic DNA and mRNA manufacturing at industry leading speed. Source: Codex investor presentation December 2021.

According to Codex' IPO prospectus, in 2020 the company's work was divided as follows:

Areas of focus: 45% biologics, 27% vaccine development, 14% cell and gene therapy, 12% genome editing and 2% agriculture.

Research area: 37% immuno-oncology, 35% infectious disease, 18% genetic/rare disease and 10% other.

Application: 23% vaccines, 21% protein engineering, 20% cell engineering, 20% antibody engineering and 16% nucleic acid engineering.

Customer type: 43% biotechnology development, 23% academic institutions, 14% pharmaceutical development, 12% other and 8% contract research.

As we can see in the slide above, Codex' systems are able to write both synthetic DNA and mRNA, and it's the latter that's likely to most interest Pfizer initially. The process of writing either is highly complex and involves multiple steps carried out by highly skilled professionals, as shown below:

Breaking down the steps required to build DNA and mRNA. Source: Codex investor presentation December 2021.

Codex' unique selling proposition is its ability to automate multiple elements of the process, thereby saving time and money, by creating a push-button, end-to-end solution that can build functional grade synthetic DNA and mRNA.

Presumably, Pfizer would wish to initially use CODEX and its BioXP system to write the SARS-Cov-2 spike protein gene that is delivered using mRNA, wrapped in a protective lipid nanoparticle ("LNP"), inside patient's cells, allowing their immune systems to create antibodies to prevent the virus gaining entry into the cell and reproducing.

It's not immediately obvious what size of contribution Codex could make to this process - Pfizer expects to manufacture ~2bn Comirnaty vaccines in 2022, which is likely to be far in advance of the biotech's capabilities, and the pharma will almost certainly have medium-term agreements in place with other manufacturers ensuring it is able to meet demand.

But if Pfizer is turning its attention to developing other types of mRNA vaccines, perhaps Codex could become its preferred development partner. It's a deal that may suit both parties, given that Pfizer will value the privacy provided by the partnership, opportunity to shape Codex' product development, and the cost saving that partnering with a smaller company will likely bring about.

Codex itself would benefit from becoming a preferred supplier of technology to Pfizer, selling large volumes of its products, and in all likelihood the biotech would become an attractive acquisition target for Pfizer, who won't want to share trade secrets with Codex' other clients - it would be wiser to bring the entire operation in-house, and Pfizer more than has the resources to do that.

Slide from Codex highlights speed and performance advantages of BioXP. Source: Codex investor presentation December 2021

When it comes to the writing / manufacturing of DNA and mRNA, speed and precision are clearly of pivotal importance, and according to Codex at least, the company has developed a competitive advantage, as we can see in the slide above.

Of course, every company will claim its own products provide a superior solution to its rivals, and it looks as though Codex does not have all bases covered yet - although the fact that Pfizer has committed itself to help develop Codex' systems ought to help the company broaden its product offering in double quick time.

Codex additionally claims that its IP portfolio is "amongst the industrys broadest and deepest synthetic biology IP portfolio," and that's another attractive selling point for Pfizer - witness the struggles Moderna has experienced contesting IP with the National Institutes of Health ("NIH") over its vaccine design and development, and with Arbutus Biopharma (ABUS) over lipid nanoparticles.

IP is tremendously important in the world of drug development, and it could be that Pfizer believes its deal with Codex will allow it to strike out alone as a developer of RNA or mRNA drugs with a partner far less mightier than e.g. BioNTech, who would gladly sacrifice some of its IP rights in exchange for a long-term partnership. It probably helps that Codex' co-founder created an entire gene assembly process, which is now named after him!

Turning to the market potential of Codex' platform and products, long term, the company views itself as capable of the "distributed manufacturing of DNA, mRNA and protein-based products," and one use-case highlighted by the company will certainly set investors pulses racing.

Codex outlines a potential response to a future pandemic. Source: Codex investor presentation December 2021.

If Pfizer is looking to future proof a rapid response to any pandemic that may emerge in the coming years, or even decades, a specialized platform that automates as many stages of mRNA vaccine design, manufacture, and distribution would be an excellent place to start, and that seems to be at least one of the company's ambitions with Codex.

Away from the pandemic, DNA, RNA and mRNA look set to play an increasingly pivotal role in the future of medicine and drug design, whether it be in the oncological, cardiovascular, autoimmune, genetic disease, or rare disease setting. Custom designing instructions to produce the right proteins in the right areas of the body is the central thesis behind the work of Moderna, BioNTech, and others more experienced mRNA drug developers, and it is an area that, until recently, was largely overlooked by larger pharmas.

Pfizer was the only pharma to develop mRNA technology in response to the pandemic, and it literally transformed the company's fortunes. In 2021, the company is likely to more than double its revenues, from ~$42bn, to ~$85bn - after seeing revenues shrink by >$10bn across the previous decade.

The big pharma had looked directionless at times over the past few years prior to the pandemic, but by stealing a march in the mRNA field it could truly become the dominant healthcare company for the next decade. The Codex deal at least hints at a company trying to cover all of its bases as quickly as possible, before its rivals catch up.

Codex is a relative minnow with a market cap scarcely above a quarter of a billion dollars, and although I have painted a rosy picture of what life could be like for the company as Pfizer's preferred partner, the reality is that big pharma's regularly make deals like this with small but promising biotechs, and as often as not, they come to nothing.

Beyond an initial $8m outlay, there's no guarantee that Pfizer will make any further investment into Codex or its technology. Arguably, Codex' technology is yet to be tested in a real world or an industrial setting, and the demands that a company such as Pfizer could place on it e.g. manufacturing the mRNA that goes into its Comirnaty vaccine - could push the company and its tech beyond breaking point.

Of course, BioNTech is a recent example of a company that flourished in partnership with Pfizer. It was a far larger company, that may not have had commercial products, but through its technology owned the key to unlocking the COVID vaccine conundrum. There are some parallels between BioNTech and Codex that may provide encouragement to an optimistic investor.

Pfizer's work with Codex does not necessarily guarantee any extra income for the biotech, and should the pharma elect not to take any products into development, Codex may continue to look like a promising company with cutting edge tech - but a dearth of paying clients. This appears to have been the chief underlying reason why the company's share price has fallen by >50% across the past 12 months.

Even a company with great technology is only as good as the companies that use that technology, and there is no shortage of competition in the DNA / mRNA writing space either.

Twist Biosciences is a good example of a company that does most of the things that Codex does, as well as many things that Codex doesn't yet do, such as DNA storage. Twist's share price has fared no better than Codex' however, down 48% across the past 12 months. Meanwhile, giants like Thermo Fisher (TMO) threaten to overwhelm the smaller competition with superior resources and a wider client base.

Codex could be one of the missing pieces that Pfizer needed to pick up on its path toward developing an mRNA therapeutics pipeline, with an initial focus on its COVID vaccine, protecting against future pandemics, and a wider focus on a range of different therapeutic modalities mentioned above.

Pfizer may have unearthed a perfect partner - a minor biotech with precisely the technology, IP protection and experienced management and staff the company needs - and Codex and its ~100 staff will likely be highly motivated to persuade the Pharma that it has all of these strengths in abundance.

That's an encouraging starting point for a deal that has largely flown under the radar, given the tiny sums involved. But the repercussions of the deal could one day be seismic for both companies.

That day is still a long, long way off, and as mentioned, pharma's experiment with the products of minor biotechs all of the time. The risk is largely on Codex' side, but it's also an opportunity to operate inside the eye of the COVID storm, prove its mettle, and make a name for itself - all of which would be transformational for its valuation.

If Pfizer believes that Codex has what it takes, it would make sense to acquire the company sooner rather than later - all of which adds up to an exciting 12 months for both companies, and a deal that, however small, should not be dismissed, and may be worth keeping a close eye on.

The rest is here:
Pfizer's Codex DNA Deal Hints At Lucrative Pivot To mRNA - Keep An Eye On This Space - Seeking Alpha

Sequence, Risk and Catan are only a few of the popular titles that can be found lining the walls of DNA Board Game Cafe in Khalidiya.

Located in Abu Dhabi's Montazah Tower, the cafe's interiors offer a striking contrast of navy blue and red with big round windows that let natural light flood in. Elsewhere, theres greenery on the walls as well as plants in the corner, adding an earthiness.

The cafe is the brainchild of Delilah Celik and Abdulaziz Alyassi, both of whom have a shared passion for playing board games. The decor is also a reflection of the couple, they tell The National.

Celik says shes a big Lord of the Rings fan, which explains the window stylings, while red is her favourite colour and navy blue is Alyassi's. Celik also loves retro vintage, a theme that can be seen throughout.

Retro vintage themes, navy blues and plush reds create the interiors of DNA Board Game Cafe in Abu Dhabi. Antonie Robertson / The National

The reason we went with a board game cafe theme is because we just love board games. Its so much fun. And we're both very competitive, says Celik. So, we were playing board games probably seven, eight years ago and then we just wanted to open our own cafe.

DNA comes from their first names, as, when they would play games together, their friends would chant D and A.

It's just a beautiful place to come with family. There's just a cosiness

Delilah Celik, co-founder

Currently, the outlet has more than 200 games that range from family-friendly to multiplayer. Some of them are strategic, while others offer more opportunity for social interaction.

Theres also a limited food menu on offer that features breakfast items such as French toast and pancakes, as well as sourdough toast options. Mains include a truffle burger on a black brioche bun and grilled tiger prawns or salad for those who want to eat lighter.

There are also cakes and desserts, as baking is another hobby that Celik enjoys. While theres plenty of space dedicated to the games, theres also a whole separate area for the baked goods. Partitioned from the rest of the cafe by a glass pane wall, the room is painted light pink with intricately decorated cakes on one side.

DNA Board Game Cafe also has a baked goods area. Antonie Robertson / The National

I love baking. I used to bake but I just don't have time now. So other people bake [for us]. But we call the space the cake basement and, originally, I did want it to be in a basement but I didnt get approvals, says Celik.

So far since opening in December, she says the cafe has had a warm reception. However, there has been some feedback on aspects such as parking, which can be limited in the busy area, as well as pricing.

Limited parking is available in the basement of the building, which people dont always realise, and Celik explains the price point: Its Dh19 per person for one hour, then Dh29 the second hour and then Dh39 for all-day rates, she says. If you're having food and drinks, that's off the menu but we wouldn't charge you while you're eating and drinking. Board games would usually go after or before.

"We usually don't mix up the games with the food because of Covid and the games would get spoiled. You can eat before but there's no table fees and it's just what you're eating from the menu.

Even though the space is new, there are already plans to expand to Ras Al Khaimah, where Alyassi is from. Celik also hopes to make more use of the "cake basement" by soon hosting cake decorating classes.

Overall, Celik says she really wants people to feel comfortable in the space, and is trying to build a sense of familiarity.

"It's just a beautiful place to come with family. There's just a cosiness," she says. "What I miss back home is there are little cafes that you'd find and everybody knows you by name. Like we're quite friendly out here."

Updated: January 8th 2022, 8:37 AM

Read more from the original source:
DNA: Abu Dhabi's new board game cafe with more than 200 options to play - The National

A WOMAN whose mom was killed and decapitated by the Time Square Killer believes there's a possibility he is her father and wants a DNA test to find out the truth.

Jennifer Weiss, 43, has been working with authorities in Bergen County, New Jersey, for years to help identify further victims of Richard Cottingham, who claims to have killed between 80 and 100 people in an 18-year spree.

4

4

Weiss' own mother was among the most infamous of Cottingham's kills, earning him the nickname The Torso Killer after he tortured and beheaded her and an unidentified 16-year-old girl in a Times Square hotel.

The body of Deedeh Goodarzi was found in a burning room on December 2, 1979, with a firefighter making the gruesome discovery that the remains were lacking heads when he attempted to give mouth to mouth.

The skull of the Iranian immigrant, who had been working as a high-end escort in Times Square, was never found.

"It's possible but not probable because of the field of work she was in," Weiss exclusively told The Sun of Cottingham being her father.

"But because it's possible, it's unsettling.

"Although we haven't done a paternity test in the court of law, my whole feeling on it is still the same because it's possible."

Weiss was given up for adoption by Goodarzi when she was less than two weeks old and there was no information given on her biological father.

Adopted by a New Jersey family, she found out the truth about her mom's death when she was 24.

First writing letters to now 75-year-old Cottingham in prison, she began to visit him in 2017 and has since met with her mom's killer more than 30 times.

She says that she does so to help bring out the truth about his other crimes and find justice for her mother and other victims.

When questioning Cottingham about the murders, he reportedly told Weiss that he had known Goodarzi for two years before he killed her, leading to her questions about whether or not he could be her father.

"If I was to pursue it in the court of law, I'd have to take him to court and do it legally," Weiss explained.

She said that she has hoped Bergan County authorities will help her in organizing the test after she has worked with the prosecutor's office in getting further information from Cottingham about his victims.

While he has said that he killed dozens of women, when Cottingham was eventually caught in the early 1980s, he was only charged and convicted with the death of five known victims.

Over the last four decades, he has admitted to a further six murders, pleading guilty to the killing of two teenagers in the 1970s as recently as April 2021.

Weiss said that she hopes a DNA test would not only prove once and for all whether or not Cottingham is her father but that it could be used to see if he has any other children apart from the three he had with his wife.

"We put his sample on the system we could see if I could be related or see if there's other children that could be related. And you know, that's just a whole other revelation," she said.

While Weiss would like to put the mystery to bed, she told The Sun that she is more interested in working to identify more victims and give families justice decades down the line.

"It would settle things for me, but it's not on top of my list," she said.

"It was never on my list until he said he'd been hanging around with Deedeh for a couple of years.

"It's a priority, but pretty low on the list. Nothing in my life will change.

"I'm still a great person and finding out that detail wouldn't change who I am."

Weiss told The Sun that she already knows of other victims of Cottingham's but that the slow pace of the official process means they have not yet been made public.

"I believe that there are other victims that were decapitated," Weiss claimed.

'You just haven't heard about them yet because we haven't had the chance to bring them to life, but they're in the lineup, for sure.

"It's an unusual thing to do to someone," she continued.

"But I think he was. He had done it many times before.

"It's just the public doesn't know that yet. I know it. But the public doesn't.

"And that's what I want. I want everyone to know the other women he killed and what he did to them.

"I have had contact with victims, family members," Weiss added.

"And that's a really good feeling.

"It doesn't come too often because these cases are so old, and most of the families are dead.

"But it's the children of the victims that have reached out and said that they were grateful for what I was doing.

"If we can work together, we could get it done quicker."

Cottingham managed to avoid detection until 1980 more than a decade after his first known murder - the killing of 29-year-old mother-of-two Nancy Vogel who was found naked and strangled in her car.

He only admitted to this killing in 2010.

Scouting for victims around Times Square, Cottingham worked a 3pm to 11pm shift in a health insurance company inManhattanwhile living with his wife and three children inNew Jersey.

He didn't leave any evidence at crimes scenes to connect the murders, leaving authorities unaware they were dealing with a serial killer.

The murderer was eventually arrested in 1980 after his wife filed for divorce and his killing spree appeared to ramp up

Cottingham was caught in the act in a hotel in New Jersey in May 1980 after the tortured screams of one of his victims alerted staff.

He had killed a woman in the very same hotel just over two weeks before.

Cottingham is serving a life sentence with no hope of parole in the New Jersey State prison.

It is believed the actual death toll of his murderous rampage will never be fully known or verified.

His story is explored in the Netflix documentary "Crime Scene: The Times Square Torso Killer" released last week.

4

4

Continue reading here:
I think the Times Square Killer who dismembered my mom is my FATHER and I want a DNA test... - The US Sun

More and more people around the world are suffering because their immune systems can no longer tell the difference between healthy cells and invading micro-organisms. Disease defences that once protected them are instead attacking their tissue and organs.

Major international research efforts are being made to fight this trend including an initiative at Londons Francis Crick Institute, where two world experts, James Lee and Carola Vinuesa, have set up separate research groups to help pinpoint the precise causes of autoimmune disease, as these conditions are known.

Numbers of autoimmune cases began to increase about 40 years ago in the west, Lee told the Observer. However, we are now seeing some emerge in countries that never had such diseases before.

For example, the biggest recent increase in inflammatory bowel disease cases has been in the Middle East and east Asia. Before that they had hardly seen the disease.

Autoimmune diseases range from type 1 diabetes to rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis. In each case, the immune system gets its wires crossed and turns on healthy tissue instead of infectious agents.

In the UK alone, at least 4 million people have developed such conditions, with some individuals suffering more than one. Internationally, it is now estimated that cases of autoimmune diseases are rising by between 3% and 9% a year. Most scientists believe environmental factors play a key role in this rise.

Human genetics hasnt altered over the past few decades, said Lee, who was previously based at Cambridge University. So something must be changing in the outside world in a way that is increasing our predisposition to autoimmune disease.

This idea was backed by Vinuesa, who was previously based at the Australian National University. She pointed to changes in diet that were occurring as more and more countries adopted western-style diets and people bought more fast food.

Fast-food diets lack certain important ingredients, such as fibre, and evidence suggests this alteration affects a persons microbiome the collection of micro-organisms that we have in our gut and which play a key role in controlling various bodily functions, Vinuesa said.

These changes in our microbiomes are then triggering autoimmune diseases, of which more than 100 types have now been discovered.

Both scientists stressed that individual susceptibilities were involved in contracting such illnesses, ailments that also include celiac disease as well as lupus, which triggers inflammation and swelling and can cause damage to various organs, including the heart.

If you dont have a certain genetic susceptibility, you wont necessarily get an autoimmune disease, no matter how many Big Macs you eat, said Vinuesa. There is not a lot we can do to halt the global spread of fast-food franchises. So instead, we are trying to understand the fundamental genetic mechanisms that underpin autoimmune diseases and make some people susceptible but others not. We want to tackle the issue at that level.

This task is possible thanks to the development of techniques that now allow scientists to pinpoint tiny DNA differences among large numbers of individuals. In this way, it is possible to identify common genetic patterns among those suffering from an autoimmune disease.

Until very recently, we just didnt have the tools to do that, but now we have this incredible power to sequence DNA on a large scale and that has changed everything, said Lee. When I started doing research, we knew about half a dozen DNA variants that were involved in triggering inflammatory bowel disease. Now we know of more than 250.

Such work lies at the core of Lee and Vinuesas efforts, which aim to find out how these different genetic pathways operate and unravel the many different types of disease doctors are now looking at. If you look at some autoimmune diseases for example, lupus it has become clear recently there are many different versions of them, that may be caused by different genetic pathways, said Vinuesa. And that has a consequence when you are trying to find the right treatment.

We have lots of potentially useful new therapies that are being developed all the time, but we dont know which patients to give them to, because we now realise we dont know exactly which version of the disease they have. And that is now a key goal for autoimmune research. We have to learn how to group and stratify patients so we can give them the right therapy.

Lee also stressed that surging cases of autoimmune diseases across the world meant new treatments and drugs were now urgently needed more than ever before. At present, there are no cures for autoimmune diseases, which usually develop in young people while they are trying to complete their education, get their first job and have families, he said.

That means growing numbers of people face surgery or will have to have regular injections for the rest of their lives. It can be grim for patients and a massive strain on health services. Hence the urgent need to find new, effective treatments.

Visit link:
Global spread of autoimmune disease blamed on western diet - The Guardian

That morning at the Idaho Falls Police Department was a slow one, which is to say an average one given the size of the town, punctuated with residents wandering in to ask about a missed jury summons or surrender old medication. And then, in the space of about half an hour, dozens of people turned up. There were tweens and great-grandmothers, toddlers and adults just to the far side of middle age, a number of the women bearing a resemblance to one another and also it was clear if you had studied the posters tacked up in the hallway to Angie Dodge, homicide victim, 6/13/1996.

Theres not a person in this city who doesnt know the story of this case, the police chief, Bryce Johnson, told me. It has defined the police department. Its part of the DNA of it. Eventually, the crowd headed down the street to watch Johnson take the lectern in the City Councils chambers, where he told the room that, the previous afternoon, near the Oregon border, officers had walked up to a 53-year-old man named Brian Leigh Dripps Sr., asked him to come in to the local police station for a chat and coaxed forth a confession. Then Moore stepped up to explain the long research process, detailing how Dripps the missing seventh direct male descendant of the right couple had evaded her; when she finally found him, she realized he had been Dodges neighbor in 1996.

This was my first time seeing Moore, and she seemed to conjure, with her long double-helix curls and black pantsuit and sleek rectangular glasses, a glamorous yet relatable detective in a TV procedural. She spoke in crisp paragraphs, with a preternatural ability to hit all her marks. (Moore has racked up dozens of IMDb credits for playing herself.) After the conference ended, she navigated effortlessly among disparate parties, including the police, judicial-reform activists, journalists and Angie Dodges mother, Carol, with whom she had been in touch throughout her investigation. In one episode of The Genetic Detective, Moore drives around Idaho Falls with Carol and works her way through Drippss superimposed family tree like Tom Cruise in Minority Report. With every victorious arrest announced, with every prime-time mention, investigative genetic genealogy was finding new audiences, wider acceptance and more opt-ins. The victim profiles were also becoming more varied, no longer just white, middle-class and female. Moore evangelized not by argument but by loving the work and looking hypercompetent while doing it.

What happened? Karole Honas, the plain-spoken doyenne of the local ABC affiliate, asked the police during the Q. and A. She meant that Dripps had no other serious legal trouble. He just went wacko bananas? Later, outside the police department, amid Mylar fund-raising pinwheels and the last falling crab-apple petals, Moore told me that, yes, in her best guess Honas was right: In the days before the murder, Drippss first child was born and his wife had been trying to leave him, and it seemed as if something had simply gone wrong in his head. Many of her cases resemble this, with offenders who commit one horrific offense and then largely stay in line, though that analysis rests on many assumptions. Only a minority of violent crimes leave behind pertinent DNA evidence, a problem that may be compounded by broad awareness of forensic science and how it can and cannot be evaded. Police noticed that one suspect identified through genetic genealogy had a three-month-old newspaper on a table, open to an article about Talbotts arrest.

On a day like that one in Idaho Falls, Moore seemed like a magician who could pull off any trick. In her final flourish, she had also cleared the name of Chris Tapp, who had served two decades for Angies murder despite having no DNA link to the crime. At the news conference, Tapp was profuse with hugs, handshakes and tears, and in another two months, he would be formally exonerated by a judge. Its the only unqualified joy Ive experienced in law-enforcement work, Moore told me. Everything else has been so heavy.

Two days later, GEDmatch became all but useless to Moore.

Following the Golden State Killer arrest, in 2018, the site had posted a warning to users that police were uploading profiles, and hastily instituted a policy restricting such use to homicides, sexual assaults and unidentified bodies. But a few weeks before the Idaho Falls announcement, it emerged that one of the sites founder-operators had, in a somewhat nave, grandfatherly way, made an exception for a detective in Utah investigating a recent attempted murder. Moore was the one tasked with identifying the suspect (and did). Around the same time, it also emerged that FamilyTreeDNA, a consumer site with more than two million users, had been discreetly allowing the F.B.I. to upload suspect profiles to its database for genetic-genealogy searches.

Continued here:
How Your DNA Test Could Send a Relative to Jail - The New York Times

The Tephra Institute of Contemporary Art will kick off the new year with the work of Laurel Nakadate, a Boston-based artist who traveled across the country to photograph familiar matches she discovered through DNA testing.

Nakadates work, which is presented in partnership with George Mason University, will be on display at the institute from Jan. 22 through May 29. The artist focuses self-representation, identify formation, representation and loneliness.

Her DNA-based series Relations began in 2013. It also features direct relatives of her mother who died shortly after Nakadate completed work on that series. Each photograph features individuals at night with a single light source at a location of their choice.

I realized at a certain point it wasnt just about the people, but it was about these landscapes. It was about standing in these landscapes and night. And it was about the sort of ways that I could still be surprised by photography, Nakadate wrote in a statement.

Tephra will also offer a first look at a series in which technicians edited photos of Nakadates mother with her newborn son, who was born shortly after Nakadates mother died.

The arts institute offered a quick look at upcoming exhibitions as well:

Travis Childers(Feb. 10-June 28): The component parts of one of Childers artworks are often recognizable manufactured objects, such as pencils or model railroad trees and figurineseven his works on canvas are comprised of images lifted from printed newspaper using scotch tape.Through a process that errs on the side of obsession, he assembles works that are deeply influenced by his personal experience of the Northern Virginia suburban landscape and his memories of a more rural childhood.In reference to a collage made from hundreds of skies excerpted from the background of published newspaper images, the artist reflects, There is just something reassuring about seeing so many horizon lines.

Danni OBrien (July 14-Oct. 11): Danni OBrien is fascinated by the history of the plastics boom that took place in the mid-twentieth century.Looming in the corner of her studio, an overburdened wire shelf serves as a library of collected refuse. Boxes and bins of found and scrapped objects are sorted intuitively by criteria such as texture, shape, material, and color.OBrien speaks about her process as caring for the objects as she meticulously integrates them into monochromatic wall mounted works, whose compositions are drawn from diagrams similarly loosened from their original contexts as instructions for home renovations, sewing, or understanding human anatomy.

Dominic Chambers (Fall 2022): Chambers most recent bodies of work feature his friends and acquaintances engaged in acts of leisure and contemplation. Too often, the Black body has been located in our imaginations as one incapable of rest, Chambers explains. Often when we imagine what the Black body is doing it is usually an act of labor, rebellion, or resistance. Instead, his subjects are depicted reading or lost in thought, their gaze fixed on points that seem far beyond the realm of the picture plane.

Image via Laurel Nakadate/Tephra Institute of Contemporary Art

See more here:
New exhibit to feature matches discovered through DNA testing - Reston Now

CLEVELAND, Ohio -- Cuyahoga County Prosecutor Michael OMalleys office has used burgeoning DNA technology to identify three men who are accused of carrying out a combined six sexual assaults across Cleveland in the 1990s.

Two of the men, who were indicted in recent years as John Doe defendants, have pleaded not guilty to charges including rape. The third man died in 2020, prosecutors said.

OMalley and Assistant Cuyahoga County Prosecutor Mary Weston said that they went as far as to get a search warrant to get a sample of the tissue of the man who died from the Cleveland Clinic, where he had been treated for pancreatic cancer, so they could test his DNA against that taken from one of the rape kits.

OMalleys office teamed up with the Texas-based genetic testing company Gene by Gene and Ohio Attorney General Dave Yosts Offices forensic crime lab to use the same technique -- and the same genealogist -- that led to the 2018 arrest of the notorious Golden State Killer.

The process, which began with grant money from the U.S. Department of Justice in 2019 and is known as the G.O.L.D. Unit, identified the first defendant earlier this year. OMalley and Weston hope it will help them identify dozens more.

Its a tremendous asset that this technology has evolved to the point that were able to do the things were doing, OMalley said.

Weston said she hopes the technology can bring solace to the minds of the women who were attacked. Weston said one of the women told her that when she stands in line at a Starbucks or in a grocery store, she sometimes wonders if the man who raped her is in line behind her.

These women dont have to look over their shoulder anymore, she said. You take that anxiety out of the equation when you solve the case, even if the person is dead.

John Doe 11

OMalleys office identified John Doe 11 as Thomas Graham, who died in October 2020 after a long battle with pancreatic cancer, according to his obituary. Graham is accused of raping three women in the citys West Side neighborhoods from 1993 to 1997.

In each case, Graham picked up women in their 20s off the street, drove them to another location and sexually assaulted them, prosecutors said.

He raped a 25-year-old woman at knifepoint on June 7, 1994, after he picked her up on Madison Avenue and drove to West 48th Street and Storer Avenue, prosecutors said. He picked up a 20-year-old woman near West 44th Street and Clark Avenue on Nov. 22, 1994, drove to Woodbridge Avenue and raped her, prosecutors said.

Four years later, on Aug. 30, 1998, Graham raped a 27-year-old woman in his car after he picked her up at Lorain Avenue and West 47th Street, prosecutors said.

Grahams DNA profile was indicted in 2013 alongside two other men known as John Doe 9 and John Doe 10.

The genealogy company the prosecutors office works with sent OMalleys office Grahams name as a potential match for John Doe 11s DNA profile earlier this year. Once investigators learned he died last year, they surreptitiously obtained an item from one of Grahams relatives and pulled their DNA off it and sent it to be tested. Investigators matched the DNA to a descendant of John Doe 11, prosecutors said.

OMalley said that since his office was unable to get a confirmation sample directly from Graham, he had his office obtain a search warrant to get a tissue sample from the Cleveland Clinic where Graham had received treatment for pancreatic cancer.

The hospital complied with the warrant and DNA testing confirmed that Grahams DNA matched John Doe 11s, prosecutors said.

Weston filed a motion to dismiss the charges against John Doe 11 as abated by death on Dec. 16.

John Doe 64

Leo Bradley Scott Jr., 60, is charged with three counts of rape and two counts of kidnapping in separate attacks of two women on Clevelands East Side in 1994 and 1998.

Prosecutors said Scott grabbed a 22-year-old woman on Oct. 14, 1994, while she was walking on Euclid Avenue near East 118th Street and dragged her to nearby train tracks, where he sexually assaulted her.

In April 1998, prosecutors say Scott pulled up to a 26-year-old woman who was walking home from a party at the Zulu Motorcycle Club and offered her a ride. When the woman said no, Scott pulled her into the car, drove to a parking lot in East Cleveland and raped her inside the car, prosecutors said.

Prosecutors indicted a DNA profile contained in the rapes as John Doe 64 in 2014.

The genealogy company identified Bradley as a potential match to the DNA profile this summer, and investigators pulled a DNA sample off of an item he had touched and testing confirmed the match. The U.S. Marshals office arrested Bradley in July.

John Doe 102

Prosecutors also identified 48-year-old Rayshawn Hundley as the man who was indicted as John Doe 102 in the burglary and rape of a 16-year-old girl on New Years Eve in 1995.

The girl, who lived in Alabama but was visiting family in Cleveland for the holidays, told police she woke up to find a strange man going through the house. The man then attacked the girl and sexually assaulted her, then stole a VCR and videotapes, prosecutors said.

Prosecutors indicted the DNA profile contained in the girls rape kit in 2015. The genealogy tests gave prosecutors the names of two possible suspects as a match for the profile, and they independently obtained samples from Hundley and matched his DNA to the profiles, prosecutors said.

Prosecutors named Hundley as a defendant in court filings in September. His trial is set for February 2022.

The girl, who was then in her early 40s, died this August as prosecutors were waiting to confirm the identity of her attacker, prosecutors said.

Read more:
Cuyahoga County prosecutors genealogical DNA unit IDs three more men accused of raping women in the 1990s - cleveland.com

Country

United States of AmericaUS Virgin IslandsUnited States Minor Outlying IslandsCanadaMexico, United Mexican StatesBahamas, Commonwealth of theCuba, Republic ofDominican RepublicHaiti, Republic ofJamaicaAfghanistanAlbania, People's Socialist Republic ofAlgeria, People's Democratic Republic ofAmerican SamoaAndorra, Principality ofAngola, Republic ofAnguillaAntarctica (the territory South of 60 deg S)Antigua and BarbudaArgentina, Argentine RepublicArmeniaArubaAustralia, Commonwealth ofAustria, Republic ofAzerbaijan, Republic ofBahrain, Kingdom ofBangladesh, People's Republic ofBarbadosBelarusBelgium, Kingdom ofBelizeBenin, People's Republic ofBermudaBhutan, Kingdom ofBolivia, Republic ofBosnia and HerzegovinaBotswana, Republic ofBouvet Island (Bouvetoya)Brazil, Federative Republic ofBritish Indian Ocean Territory (Chagos Archipelago)British Virgin IslandsBrunei DarussalamBulgaria, People's Republic ofBurkina FasoBurundi, Republic ofCambodia, Kingdom ofCameroon, United Republic ofCape Verde, Republic ofCayman IslandsCentral African RepublicChad, Republic ofChile, Republic ofChina, People's Republic ofChristmas IslandCocos (Keeling) IslandsColombia, Republic ofComoros, Union of theCongo, Democratic Republic ofCongo, People's Republic ofCook IslandsCosta Rica, Republic ofCote D'Ivoire, Ivory Coast, Republic of theCyprus, Republic ofCzech RepublicDenmark, Kingdom ofDjibouti, Republic ofDominica, Commonwealth ofEcuador, Republic ofEgypt, Arab Republic ofEl Salvador, Republic ofEquatorial Guinea, Republic ofEritreaEstoniaEthiopiaFaeroe IslandsFalkland Islands (Malvinas)Fiji, Republic of the Fiji IslandsFinland, Republic ofFrance, French RepublicFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabon, Gabonese RepublicGambia, Republic of theGeorgiaGermanyGhana, Republic ofGibraltarGreece, Hellenic RepublicGreenlandGrenadaGuadaloupeGuamGuatemala, Republic ofGuinea, RevolutionaryPeople's Rep'c ofGuinea-Bissau, Republic ofGuyana, Republic ofHeard and McDonald IslandsHoly See (Vatican City State)Honduras, Republic ofHong Kong, Special Administrative Region of ChinaHrvatska (Croatia)Hungary, Hungarian People's RepublicIceland, Republic ofIndia, Republic ofIndonesia, Republic ofIran, Islamic Republic ofIraq, Republic ofIrelandIsrael, State ofItaly, Italian RepublicJapanJordan, Hashemite Kingdom ofKazakhstan, Republic ofKenya, Republic ofKiribati, Republic ofKorea, Democratic People's Republic ofKorea, Republic ofKuwait, State ofKyrgyz RepublicLao People's Democratic RepublicLatviaLebanon, Lebanese RepublicLesotho, Kingdom ofLiberia, Republic ofLibyan Arab JamahiriyaLiechtenstein, Principality ofLithuaniaLuxembourg, Grand Duchy ofMacao, Special Administrative Region of ChinaMacedonia, the former Yugoslav Republic ofMadagascar, Republic ofMalawi, Republic ofMalaysiaMaldives, Republic ofMali, Republic ofMalta, Republic ofMarshall IslandsMartiniqueMauritania, Islamic Republic ofMauritiusMayotteMicronesia, Federated States ofMoldova, Republic ofMonaco, Principality ofMongolia, Mongolian People's RepublicMontserratMorocco, Kingdom ofMozambique, People's Republic ofMyanmarNamibiaNauru, Republic ofNepal, Kingdom ofNetherlands AntillesNetherlands, Kingdom of theNew CaledoniaNew ZealandNicaragua, Republic ofNiger, Republic of theNigeria, Federal Republic ofNiue, Republic ofNorfolk IslandNorthern Mariana IslandsNorway, Kingdom ofOman, Sultanate ofPakistan, Islamic Republic ofPalauPalestinian Territory, OccupiedPanama, Republic ofPapua New GuineaParaguay, Republic ofPeru, Republic ofPhilippines, Republic of thePitcairn IslandPoland, Polish People's RepublicPortugal, Portuguese RepublicPuerto RicoQatar, State ofReunionRomania, Socialist Republic ofRussian FederationRwanda, Rwandese RepublicSamoa, Independent State ofSan Marino, Republic ofSao Tome and Principe, Democratic Republic ofSaudi Arabia, Kingdom ofSenegal, Republic ofSerbia and MontenegroSeychelles, Republic ofSierra Leone, Republic ofSingapore, Republic ofSlovakia (Slovak Republic)SloveniaSolomon IslandsSomalia, Somali RepublicSouth Africa, Republic ofSouth Georgia and the South Sandwich IslandsSpain, Spanish StateSri Lanka, Democratic Socialist Republic ofSt. HelenaSt. Kitts and NevisSt. LuciaSt. Pierre and MiquelonSt. Vincent and the GrenadinesSudan, Democratic Republic of theSuriname, Republic ofSvalbard & Jan Mayen IslandsSwaziland, Kingdom ofSweden, Kingdom ofSwitzerland, Swiss ConfederationSyrian Arab RepublicTaiwan, Province of ChinaTajikistanTanzania, United Republic ofThailand, Kingdom ofTimor-Leste, Democratic Republic ofTogo, Togolese RepublicTokelau (Tokelau Islands)Tonga, Kingdom ofTrinidad and Tobago, Republic ofTunisia, Republic ofTurkey, Republic ofTurkmenistanTurks and Caicos IslandsTuvaluUganda, Republic ofUkraineUnited Arab EmiratesUnited Kingdom of Great Britain & N. IrelandUruguay, Eastern Republic ofUzbekistanVanuatuVenezuela, Bolivarian Republic ofViet Nam, Socialist Republic ofWallis and Futuna IslandsWestern SaharaYemenZambia, Republic ofZimbabwe

Read more:
DNA evidence processed in Amory homicide investigation | News | djournal.com - Northeast Mississippi Daily Journal

A plop of rain met parched California ground and trickled into a creek. There it scraped against fish and slipped through their gills, stealing traces of each encounter. The droplet then carried the genetic souvenirs downstream until it reached an innovative device that helped unlock the secrets of the creeks creatures.

We call this a microbiology lab in a can, said Jim Birch, director of the SURF center at the Moss Landing-based Monterey Bay Aquarium Research Institute.

That can is actually MBARIs environmental sample processor, a $200,000 robotic laboratory the size of a 50-gallon drum. It gathers genetic clues cells, mucus, feces from ecosystems that are collectively dubbed environmental DNA, or eDNA.

In a project on Scott Creek north of Davenport, the device produced one of the nations largest single-site eDNA data collections. From April 2019 to April 2020, scientists uncovered details about endangered and invasive species in the freshwater ecosystem. Now a scientific paper in the works, the study reinforces the growing interest in detecting and better protecting hard-to-find species using eDNA monitoring instead of more invasive techniques such as fish counts.

It has that ability to do that without having to put a lot of nets in the water, said MBARIs Kevan Yamahara, a specialist on the device and one of the papers authors.

Worldwide interest in eDNAs ability to detect rare organisms has expanded over the past few decades. The new technology rediscovered a rare aquatic insect population in the United Kingdom. It detected more mammals than traditional camera traps in the Canadian wilderness. It helped track the spread of the coronavirus.

In Scott Creek, MBARIs device pumped water from the creeks flow and pushed it through a filter several times a day. Once the filter collected enough materials, the machine applied a preservative. According to Yamahara, each filter was then shelved in a carousel similar to the bullet-loaded chamber of a gun. Once the carousel filled with 132 samples, researchers collected the data and brought it to their Moss Landing lab.

Nearly 700 samples emerged from the yearlong monitoring. Researchers focused on the creeks endangered coho salmon and threatened steelhead trout populations, both commercially important fish. Since Scott Creek is one of the southernmost points where coho salmon come to lay eggs, its crucial to know how the species is faring, said Birch, who is also an author of the soon-to-be-submitted research manuscript.

In the creek, the device sat next to a more established monitoring tool: a weir operated by the National Oceanic and Atmospheric Administration. Birch said that the weir, a perforated flow-through dam, has allowed NOAA staff to tally, inspect and release fish on a seasonal basis for two decades.

The fish counts continued throughout the project and allowed for comparisons of traditional and emerging monitoring techniques. From the samples, the team gleaned that the amount of steelhead trout DNA usually surpassed that of coho salmon. This complemented the numbers observed in the NOAA fish traps, according to Ryan Searcy, an environmental engineering doctoral student at Stanford and the research papers lead author.

The collected eDNA also provided seasonal data that mirrored the suspected life histories of species through winter rains, summer dry spells and most days in between. The information unveiled the best times to conduct eDNA sampling for certain species, Yamahara said.

The highest concentrations of coho salmon eDNA, for example, appeared during the winter when the fish were thought to be migrating and laying eggs. During the fall, when the creeks flow diminished, so did the amount of salmon eDNA. The findings gave researchers confidence in the data and suggested that the new monitoring methods could be well-suited for documenting the behaviors of migratory fish, Searcy said.

The data revealed other secrets of the creek: The team found that less than 1% of the eDNA came from invasive species. That low number offers hope that species like the New Zealand mudsnail and striped bass are not yet present in the creek, Searcy said. Such monitoring could offer scientists early warning signs for invasive species before ever observing them, Yamahara said.

You dont have to actually physically go and physically look for those specimens, Yamahara said. You can just take a water sample and process it.

MBARIs environmental sample processor traveled around the world when it was unveiled in the late 2000s, Birch said. The version of the Scott Creek device has since transformed into a new model the size of two basketballs.

Researchers included the upgraded tech in underwater autonomous vehicles now used to explore marine habitats like those in Monterey Bay, Birch said. Theyre also used in the Great Lakes to track harmful algae blooms, Yamahara said.

As eDNA monitoring evolves from stationary machinery to traveling endeavors across ecosystems, Yamahara hopes that the technology will progress even more for use in freshwater habitats like Scott Creek. But while the device could revolutionize ecosystem monitoring, the prototype has limitations.

The sheer amount of genetic information the new devices provide, for instance, can overwhelm labs, Birch said. To fix this problem, hed like to see future versions of the tech do that analysis on-site.

Thats really the Holy Grail the brass ring that we are trying to push for here at MBARI to go beyond the simple sampling and do the processing onboard as well, he said.

There were also discrepancies between old and new monitoring strategies. The team detected fish eDNA more frequently than the fish were counted in NOAAs fish traps. Thats unexpected but not unheard of in the field, according to Searcy, especially since detected eDNA could belong to fish upstream of the sampling site.

Since each technique reveals different details about species, they should be seen as complementary at this point, the researchers say. That combination is valuable and rare in the greater Bay Area, said Brian Allee, the lead fisheries biologist at the South Bay Clean Creeks Coalition who was not involved in the study.

While the devices price tag can limit its use, Allee would like to see its eDNA monitoring applied to local urban streams to further investigate endangered species.

What we really want are wild populations spawning on their own on a sustainable basis, he said. That has been a difficult process one in which technology is important since we cant turn the clock back to the Lewis and Clark era.

Originally posted here:
Environmental DNA reveals the secrets of a California creek and beyond - The Mercury News